Collaboration in more than 46 countries.

You are leaving the country website to access another site in the group. Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.

NORTH AMERICA

Canada

United States

LATIN AMERICA

Argentina

Brazil

Mexico

Perú

GLOBAL

CEVA Global

EMEA (REGIONAL)

Denmark

Egypt

France

Germany

Hungary

Italy

Netherlands

Poland

Portugal

Romania

South Africa

Spain

Sweden

Tunisia

Turkey

Ukraine

United Kingdom

ASIA PACIFIC

Asia Pacific (Regional)

CHINA

India

Indonesia

Japan

Korea

Malaysia

Philippines

Publications
PDF

Poster-Zeleris-2_Achard-WBC-2018.pdf

Open PDF

Summary

In this experimental study, the florfenicol and meloxicam combination (Zeleris®) was found to be highly effective for the treatment of BRD (cure rate = 100%). Calves treated with this new combination were moreover at lower risk for clinical relapse and presented a higher bodyweight gain compared to calves receiving the florfenicol and flunixin meglumine combination. These results are in line with the pharmacokinetic properties of florfenicol and meloxicam.

Share this publication:

Publication file:

Download publication
This site is registered on wpml.org as a development site.